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INTRODUCTION
Idiopathic hypoparathyroidism is an endocrine disorder
characterized by hypocalcemia and hyperphosphatemia due
to impaired secretion of parathyroid hormone (PTH). Molec-
ular genetic studies have elucidated the dynamic pathogen-
esis of idiopathic hypoparathyroidism. It may occur as part
of a polyglandular autoimmune disorder or as a complex con-
genital defect, such as in DiGeorge’s syndrome. In addition,
it may occur as a solitary endocrinopathy which is called iso-
lated hypoparathyroidism. Isolated hypoparathyroidism may
be caused by a mutation in the PTH gene, glial cells miss-
ing (GCM)2 gene or calcium-sensing receptor (CaSR) gene
(1, 2).
Gain-of-function mutations in the CaSR gene cause famil-
ial hypocalcemia (3). Here we report a Korean family with
two affected siblings and their phenotypically silent father,
who were found to carry mutations in the CaSR gene. This
case is the first report in Korea.
CASE REPORT
A 24-yr-old woman was seen in the endocrinology clinic
at Samsung Medical Center because of transient numbness
and periodic paralysis. The patient reported that the symp-
toms started 10 yr ago. The patient experienced occasional,
brief episodes of paralysis during exertion that resolved with
rest. Mild numbness and tingling of the hands and feet were
also present intermittently. 
On examination, the patient appeared well. Her vital signs
were normal; her height was 155 cm, and her weight was
44 kg. Neurologic examination was significant for positive
Trousseau and Chvostek signs. The remainder of the physi-
cal examination was normal. Laboratory tests revealed hypo-
calcemia (7.3 mg/dL; reference range 8.4-10.2), hyperphos-
phatemia (5.7 mg/dL: reference range 2.5-4.5), decreased
1,25-dihydroxycholecalciferol ([1,25(OH)2D] 13.2 pg/mL:
reference range 25.1-66.1), and decreased iPTH (4.9 pg/mL:
reference range 10-65). 25-hydroxycholecalciferol ([25(OH)D]
20.2 ng/mL: reference range 11-70) and 24-hr urinary calci-
um excretion was normal as were bone densitometry, thy-
roid functions tests, and radiographs of the kidney, ureter,
bladder (KUB) and skull. The patient was treated with cal-
cium carbonate and alfacalcidol with resolution of symptoms
and dosages were adjusted to maintain a serum calcium level
within the lower end of the normal reference range.
The older brother of the proband had a history of general-
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Autosomal Dominant Hypocalcemia Caused by an Activating Mutation
of the Calcium-Sensing Receptor Gene: The First Case Report in Korea
Hypoparathyroidism is an abnormality of calcium metabolism characterized by low
serum levels of parathyroid hormone in spite of hypocalcemia. The causes of hypo-
parathyroidism are numerous. Activating mutations in the calcium-sensing recep-
tor (CaSR) gene are well-known causes of familial isolated hypoparathyroidism,
also known as autosomal dominant hypocalcemia (ADH). Here we describe mem-
bers of a Korean family with a heterozygous Pro221Leu mutation causing ADH.
This case is the first report in Korea.
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by a neurologist at an outside hospital. He also presented to
Samsung Medical Center with his sister because of intractable
seizure. Initial evaluation revealed a serum calcium concen-
tration of 7.5 mg/dL (reference range 8.4-10.2), a serum phos-
phorus concentration of 6.1 mg/dL (reference range 2.5-4.5),
and a serum magnesium concentration of 1.9 mg/dL (refer-
ence range 1.9-2.5). The serum concentration of iPTH level
was 6.2 pg/mL (reference range 10-65). He was treated with
an antiepileptic medication and calcium carbonate, but seizure
activity persisted. He was taking calcium carbonate 3 g per
day with antiepileptic drug. He was admitted to the neurolo-
gy ward where he underwent EEG and brain imaging. The
laboratory test on admission showed a serum calcium con-
centration of 7.1 mg/dL (reference range 8.4-10.2), a serum
phosphorus concentration of 5.6 mg/dL (reference range 2.5-
4.5), and a serum ionized calcium concentration of 0.92 mM/L
(reference range 1.05-1.35). Brain magnetic resonance imag-
ing showed non-physiologic calcifications in the basal gan-
glia, bilateral frontal lobes, and cerebellum. The EEG was
normal. A dosage of calcium supplement was adjusted, and
alfacalcidol was added. He reported subsequent absence of
seizure activity during follow-up. During follow-up the cal-
cium level increased up to 8.3 mg/dL (reference range 8.4-
10.2) and the ionized calcium level increased up to 1.0 mM/L
(reference range 1.05-1.35). After seizure activity subsided,
he is followed-up by the physician near the home. 
Although the parents of patients denied symptoms attribu-
table to hypocalcemia, they agreed to evaluation. Laboratory
examination of their father revealed hypocalcemia, hyper-
phosphatemia, and an inappropriately low PTH level. The
results of laboratory test are shown on Table 1. The mother’s
laboratory work-up was normal. The remaining members of
the family were not included in this study because of inac-
cessibility (Fig. 1).
DNA analysis
After we obtained informed consent, the proband and her
family members were examined to detect the CaSR muta-
tions by direct sequencing analysis. Genomic DNA was ex-
tracted from blood using a Wizard genomic DNA purifica-
tion kit (Promega, Madison, WI, USA). Each of the 6 exons
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N/A, not available; Ca, calcium; Mg, magnesium; TSH, thyroid stimulat-
ing hormone.
Reference 
Proband Sibling Father Mother range
Ca, ionized (mM/L) 1.05-1.35 0.91 0.95 0.80 1.30
Ca, total (mg/dL) 8.4-10.2 7.3 7.5 6.41 9.35
Phosphate (mg/dL) 2.5-4.5 5.7 6.1 4.62 3.8
Mg (mg/dL) 1.9-2.5 2.0 1.9 2.06 N/A
iPTH (pg/mL) 10-65 4.9 6.2 13.5 27.2
T3 (ng/dL) 76-190 122 115 95 N/A
T4 (mg/dL) 4.7-12.5 8.4 9.7 N/A N/A
Free T4 (ng/dL) 0.79-1.86 N/A N/A 1.43 N/A
TSH (mU/L) 0.30-6.50 2.63 2.34 1.46 N/A
24-hr urine Ca (mg) 100-240 126 204 N/A N/A
Table 1. Biochemical features of three affected and a non-affect-
ed family members
Gene test: not done
Mutation in CaSR gene: positive
Mutation in CaSR gene: negative 
Proband
Fig. 1. The pedigree of the family. One of the uncles deceased in
his third decade without clear cause. Closed black circles indicate
the affected persons (proband, sibling, and father). The arrow in-
dicates the proband. Closed gray circle indicates proband’s moth-
er without mutation in calcium-sensing receptor (CaSR) gene. The
remaining members of the family (open circles) were not includ-
ed in this study because of inaccessibility.
CaSR-Exon01-F ACTGCAGGGAGTGAACTGCT
CaSR-Exon01-R AGGTTGTGGGGGCAATAAG
CaSR-Exon02-1-F GCCATGTCATCCCCATTTTA
CaSR-Exon02-1-R CGCCTGAGAAGGCTTGAGTA
CaSR-Exon02-2-F GTGGGTTTCGCTGGTTACAG
CaSR-Exon02-2-R TCAGAAATCCCAAATGGTCA
CaSR-Exon03-1-F GATGCTGCTTTTCCTTACCC
CaSR-Exon03-1-R CCACTGGAGAAAACCACGAT
CaSR-Exon03-2-F GAACCATCCCCAATGATGAG
CaSR-Exon03-2-R ACTCCTTGGCAAAACCATTG
CaSR-Exon03-3-F TCCAGCATGTGGTAGAGGTG
CaSR-Exon03-3-R AGGATATCCGTAAATGCGTGT
CaSR-Exon03-4-F ACAATGGTTTTGCCAAGGAG
CaSR-Exon03-4-R TGCCCTTTTCAAATGACCAC
CaSR-Exon04-F CACGTTCCTCCCACTTTGTT
CaSR-Exon04-R CAAAGGCCAGAGAGTTCAGG
CaSR-Exon05-F TGCACATGTGTGTGTGTGTG
CaSR-Exon05-R AGAAACTGTGCAAAGCACCA
CaSR-Exon06-1-F TCAGAATGATTTCAGCAAAATGG
CaSR-Exon06-1-R ATGCATGAGATGCAGAGCAC
CaSR-Exon06-2-F GCATTTTCCTGACAGCCTTT
CaSR-Exon06-2-R TGGCACGTGATGAAGATGAT
CaSR-Exon06-3-F CATCTCATGCATCCTGGTGA
CaSR-Exon06-3-R AAGATGCACGCCAGCAAG
CaSR-Exon06-4-F GCCATCTGCTTCTTCTTTGC
CaSR-Exon06-4-R CTGCTGCTCTTGCTGGGTTA
CaSR-Exon06-5-F CATCGAGGAGGTGCGTTG
CaSR-Exon06-5-R TCCTTGCAGACCTGTTTCCT
CaSR-Exon06-6-F CAGATGCAAGCAGAAGGTCA
CaSR-Exon06-6-R GACTAAATTCGGGGCATTTG
Table 2. Intronic primer sets of calcium-sensing receptor (CaSR)
geneof the CaSR gene were amplified by polymerase chain reac-
tion using appropriate intronic primer sets designed by the
authors (Table 2). Cycle sequencing was performed with a
BigDye Terminator Cycle Sequencing Ready Reaction kit
(Applied Biosystems, Foster City, CA, USA) on the ABI-
3100 Genetic Analyzer (Applied Biosystems).
Direct sequencing showed that all affected family mem-
bers have a C to T transition at nucleotide 662 resulting in
a Pro221Leu missense mutation in exon 3 of the CaSR gene
(Fig. 2). 
DISCUSSION
In recent years, important advances in endocrinology have
resulted from the application of the methods of molecular
biology. These advances have helped not only to demonstrate
the roles of mutant genes in the etiology of some inherited
disorders, but have also helped to identify the chromosomal
locations of susceptibility genes that predispose individuals
at risk for a particular disorder such as familial hypocalcemia.
The results of the studies on the molecular genetics of the
hypoparathyroid disorders have helped to elucidate some of
the underlying pathways that are involved in calcium home-
ostasis (1).
Theoretically, hypocalcemic disorders can be caused by
deficiency of PTH, by a defect in the PTH/PTHrP receptor,
or by insensitivity to PTH caused by defects downstream of
the PTH/PTHrP receptor. The mutations in several genes
such as CaSR (4), PTH (5), GCM2 and GATA3 (6) have been
shown to cause hypoparathyroidism. Among them mutations
in CaSR and PTH show autosomal dominant inherited forms
of isolated hypoparathyroidism. GATA3 mutation is inher-
ited autosomal dominantly, but it usually accompanied by
multiple anomalies such as deafness and renal impairment
(1, 2). Proband and her family member had hypocalcemia
in conjunction with low PTH level, and a defect in the PTH/
PTHrP receptor and insensitivity to PTH could be exclud-
ed. The absence of associated anomalies could partly exclude
the mutations in GCM2 and GATA3 genes. 
In 1993, it was discovered that the mutation of the CaSR
gene causes familial hypocalciuric hypercalcemia and severe
neonatal hyperparathyroidism. Subsequently, it was learned
that a loss-of-function mutation causes hypercalcemia and
gain-of-function mutation causes hypocalcemia (4), which
is called autosomal dominant hypocalcemia (ADH).
The CaSR gene is located on chromosome 3q13.3-q21,
and it encodes a cell surface protein of 1078 amino acids that
is expressed in the PTH-producing chief cells of the parathy-
roid glands and also in cells lining the kidney tubule. The
CaSR belongs to the family of G-protein-coupled receptors
(3, 7, 8). The CaSR in the parathyroid gland detects small
changes of extracellular calcium concentration and regulates
transcription of the PTH gene. The CaSR that is expressed
in the distal renal tubule regulates renal calcium excretion
(1). Thus, the CaSR is vital to maintaining normal serum cal-
cium levels (9). Loss-of-function mutations in the CaSR gene
are associated with a severe neonatal hyperparathyroidism
and familial hypocalciuric hypercalcemia. Gain-of-function
mutations in the CaSR gene are associated with a familial
hypocalcemia (3). Since Pollack et al. reported an activating
mutation in the N-terminal, extracellular domain of the CaSR
gene (4), several activating mutations in the CaSR gene have
been reported (9). Currently, there is a database of mutations
of CaSR available on the internet (http://www.casrdb.mcgill.
ca/) which lists all the known CaSR mutations and their effects
(10). Pro221Leu missense mutation was first reported in 2000,
and the mutation is located in a lesion of the extracellular
domain of the receptor. Replacement of a large, rigid proline
with a smaller and more flexible leucine residue, potentially
changing the conformation of the calcium-binding region
to resemble that of bound calcium or facilitating the bind-
ing of calcium ions, resulting in an active mechanism (11).
Four more cases were reported in CaSR database after 2000. 
It is important to distinguish hypocalcemia due to an acti-
vating mutation of CaSR from isolated hypoparathyroidism
because ADH patients can develop nephrocalcinosis and renal
impairment during treatment with calcium and vitamin D.
The distinction between isolated hypoparathyroidism and
ADH may be difficult to make on based on clinical informa-
tion alone. Therefore, mutational analysis of the CaSR gene
can be considered to assess the risk of nephrocalcinosis dur-
ing treatment of PTH-deficient hypoparathyroidism (12).
In conclusion, although a case of familial benign hypocal-
ciuric hypercalcemia due to a loss-of-function mutation in the
CaSR gene has been reported in Korea (13), a gain-of-func-
tion mutation of the CaSR gene that causes familial hypocal-
cemia has not yet to be reported in Korea. Here we have des-
cribed the first Korean family with ADH with a review of
the literature.
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Father: 
Pro221Leu(+)
Mother: 
Pro221Leu(-)
Sibling: 
Pro221Leu(+)
Proband: 
Pro221Leu(+)
Fig. 2. Direct sequencing of the calcium-sensing receptor (CaSR)
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